Date:	4/8/2025
Your Name:	Dominantly Inherited Alzheimer Network
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None None	Click the tab key to add additional rows.
		Time frame: past 36 month:	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None  NIH Grant # U19AG032438  Alzheimer's Association grant – SG-20-690363- DIAN Latin America	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	3/9/2025
Your Name:	Haiyan Liu
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	X	None	Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.			
			Time frame: past 36 month	ıs
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Plea	se place an "X" next	to the following statement to indicate your agreemen	nt:
Χ	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/6/2024
Your Name:	Quoc Bui
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscrint Number (if known):	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not	Х	None	
	indicated in item #1 above).			
	#1 above).			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
	Please place an "X" next to the following statement to indicate your agreement:		

Date:		3/11/2024		
Your Name:		Jason Hassenstab		
Manuscript Title:		Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease		
Ma	nuscript Number (if k	nown): ADJ-D-24-02652		
content of your manuscript. "Rela affected by the content of the ma		ency, we ask you to disclose all relationships/activities/interests listed below that are related to the ot. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate about whether to list a relationship/activity/interest, it is preferable that you do so.		
		/activities/interests should be defined broadly. For example, if your manuscript pertains to the sion, you should declare all relationships with manufacturers of antihypertensive medication, even if ntioned in the manuscript.		
	em #1 below, report ne for disclosure is th	Il support for the work reported in this manuscript without time limit. For all other items, the time past 36 months.		
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	None  NIH Grants for work listed in manuscript already  Click the tab key to add additional rows.		
	article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not	X None		
	indicated in item #1 above).			
Royalties or licenses X No.		X None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments we made to you or to your institution)	
4	Consulting fees	Parabon Nanolabs Roche AlzPath Personal payments Personal payments Personal payments	
		Prothena	Personal payments
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None  Caring Bridge: NIA sponsored  Wall-E: NIA sponsored	Personal payments Personal payments

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

912/13/2021ICMJE Disclosure Form

Date:	3/7/2024
Your Name:	Brian A. Gordon
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work				
	All support for the present manuscript (e.g., funding, provision	Х	None		
	of study materials,				
	medical writing, article processing			Click the tab key to add additional rows.	
	charges, etc.) No time limit for this item.				
			Time frame: past 36 month	s	
2	Grants or contracts from any entity (if not	Х	None		
	indicated in item #1 above).				
	#1 abovej.	—			
3	Royalties or licenses	Х	None		
		$\vdash$			
	,	—			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Please place an "X" next to the following statement to indicate your agreement:  X   Legacian   Leg			

Date:			3/15/2024		
Your Name: Manuscript Title:			Tammie L.S. Benzinger		
			Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease		
Maı	nuscript Number (if k	(nown):	ADJ-D-24-02652		
content of your manuscript. "Rela affected by the content of the ma		ipt. "Rela of the ma	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily indicate whether to list a relationship/activity/interest, it is preferable that you do so.		
		nsion, yo		xample, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ <b>N</b>	one	Payments to institution  Click the tab key to add additional rows.	
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not		one		
	indicated in item #1 above).	Siemer	ns	Payments to institution	
3	Royalties or licenses	X N	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None  Biogen Payments to me	
		Eli Lilly Eisai Siemens Bristol Myers Squibb	Payments to me Payments to me Unpaid Payments to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None  Biogen Eisai	Payments to me Payments to me
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None  Eisai Siemens NIH sponsored/External advisor on several grants Eli Lilly	Payments to me  No payments made  No payments other than travel reimbursement  Payments to me

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if paym made to you or to your institution)			
		Bristol Myers Squibb	Payments to me		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	ASNR Alzheimer's and ARIA Study group QIBA Amyloid PET Working Group Alzheimer's Assoc. Clinical Tau PET Work Group American College of Radiology/AlzNet Work Group	Unpaid Unpaid Unpaid Unpaid Unpaid		
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None  Avid Radiopharmaceuticals/Eli Lilly  LMI  Cerveau/Lantheus	Technology transfer and precursors for radiopharmaceuticals (18F-Florbetapir, 18FFlortaucipir)  Technology transfer and precursors for radiopharmaceuticals (18F-PI-2620)  Technology transfer and precursors for radiopharmaceuticals (18F-MK-6240)		
13	Other financial or non-financial interests	X None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				
Χ	I certify that I have	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	3/7/2024	
Your Name:	Jigyasha Timsina	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADI-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
charges, etc.)  No time limit for				
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	Х	None	
	indicated in item #1 above).			
	"I above,"			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Please place an "X" next to the following statement to indicate your agreement:  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	3/9/2024
Your Name:	Yun Ju Sung
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g.,	Х	None	
	funding, provision of study materials,			
	medical writing,			Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item	х	None	
	#1 above).			
3	Royalties or licenses	X	None	
4	Consulting fees	X	None	
5	Payment or honoraria for lectures, presentations,	Х	None	
	speakers			
	bureaus,			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	manuscript writing or educational events		
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Plea X	Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/17/2024
Your Name:	Celeste Karch
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		ities with whom you have this or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
All support for the present manuscript (e.g.,	X None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	S
3	Royalties or licenses	X None	
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Please place an "X" next to the following statement to indicate your agreement:				
Х	X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	3/21/2024
Your Name:	Alan E. Renton
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g.,	□ None	
	funding, provision of study materials,	National Institute on Aging	Payment made to institution
med artid chai <b>No</b> 1	medical writing,		Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 months	5

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	□ None  National Institute on Aging	Payment made to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Please place an "X" next to the following statement to indicate your agreement:			
χ			

Date:	3/19/2024
Your Name:	Alisha Daniels
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
pr ma	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	Х	None	
	indicated in item #1 above).			
	"I above,"			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	3/16/2024
Your Name:	John C. Morris
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X None	Click the tab key to add additional rows.
		<b>-</b>	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 month  ☐ None  NIH support: P30 AG066444; P01AG003991; P01AG026276; U19AG032438	s
3	Royalties or licenses	X None	
4	Consulting fees	□ None  Barcelona Brain Research Center BBRC)	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	□ None  Montefiore Grand Rounds, NY  Tetra-Inst ADRC seminar series, Grand Rds, NY	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	manuscript writing or educational events		
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None  Cure Alzheimer's Fund, Research Strategy Council Diverse VCID Observational Study Monitoring Board LEADS Advisory Board, Indiana University	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	

		lame all entities with whom you have this elationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None
13	Other financial or non-financial interests	X None
Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/24/2024
Your Name:	Chengjie Xiong
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease

Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	Click the tab key to add additional rows.		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ <b>None</b> NIH grant AG067505, and R01 AG053550.	Payments made to institution		
3	Royalties or licenses	X None			
4	Consulting fees	□ None  Diadem	Payment received by Dr. Chengjie Xiong		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None  FDA Advisory Committee on Imaging Medical Products	Dr. Chengjie Xiong
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None			
13	Other financial or non-financial interests	C2N Diagnostics	Work citing NIH grant #AG067505 requires an institutional disclosure. Washington University School of Medicine in St. Louis has a financial interest in C2N Diagnostics and may financially benefit if the company is successful in marketing its product(s) that are related to this research. The current study is not directly concerned by this statement as it does not utilize data from this project.		
Plea X	Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	3/14/2024
Your Name:	Laura Ibanez
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease

Manuscript N	Number (i	if known)	): A	۱D.	I-D	-24-	-02	652
--------------	-----------	-----------	------	-----	-----	------	-----	-----

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	X None	Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.		
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
			_
4	Consulting fees	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	3/9/2025		
Your Name:	Richard J. Perrin		
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease		
Manuscript Number (if known):	ADJ-D-24-02652		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None	
	funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	U19 AG032438 (Bateman) 09/15/19-06/30/24 U19AG032438-09S1 (Bateman) 09/2019-06/2024 R01AG068319 (Bateman) 09/15/20-05/31/25 R01 AG053267 (Bateman) 09/01/17-05/31/22	Institution
			Click the tab key to add additional rows.
		Time frame: past 36 month	is
2	Grants or contracts from any entity (if not	□ None	
	indicated in item #1 above).	P01 AG003991 (Morris) 05/01/19-04/30/24 P30 AG066444 (Morris) 05/01/20-04/30/25 R01AG054567 (Benzinger)09/15/17-06/30/22 R01 AG052550 (Benzinger)04/15/18-01/31/23 R01 AG070883 (Kind, Raji)03/01/21-02/28/26 R01NS092865 (Xu) 02/01/16-11/30/21 R01AG054513(Yablonskiy)07/01/17-04/30/22 R01	All to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		NS075321(Perlmutter)05/01/11-04/30/22 NCE APDA (Perlmutter) 01/01/99-08/2023 R01NS097799 (Kotzbauer)07/2022-06/2027 U19AG069701 (Bu) 06/2021-05/2026	
		U19NS110456 (Perlmutter) 09/2019-06/2024 R01AG058676 (Masters) 09/2018-05/2024 NCE R01AG074909 (Q Wang) 04/2022-01/2027 U19AG024904 (Weiner) 09/2022-07/2027 U19AG07879 (Ertekin-Taner) 03/2023-02/2027	All to institution
3	Royalties or licenses	X None	
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	□ None  Biogen	Dr. Perrin's laboratory receives cost recovery funding from Biogen for tissue procurement and processing services related to ALS clinical trials.

Name all entities with whom you have this	Specifications/Comments (e.g., if payments were
relationship or indicate none (add rows as needed)	made to you or to your institution)

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	3/9/2025
Your Name:	Jorge J Llibre-Guerra
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652
In the interest of transparency, we	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	□ None  NIH-NIA (K01AG073526)  Alzheimer's Association (AARFD-21-851415)	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None  NIH-NIA (K01AG073526)  Alzheimer's Association (AARFD-21-851415)  Alzheimer's Association (SG-20-690363)	
3	Royalties or licenses	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	3/23/20254	
Your Name:	Gregory S. Day	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	present manuscript (e.g.,	X None	
	funding, provision of study materials,		
	medical writing, article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item	□ <b>None</b> NIH/NIA: K23AG064029, U01AG057195;	
	#1 above).	U19AG032438 NIH/NINDS: U01NS120901	
		Chan Zuckerberg Assoc Alzheimer's Association (LDRFP-21-824473	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	X None	
4	Consulting fees	□ None  Parabon Nanolabs	Payments to me for work on NIH small business grant
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	PeerView Media Continuing Education, Inc Eli Lilly DynaMed	CME development + presentation (personal)  CME development + presentation (personal)  Content development + presentation (payment to institution)  Topic editor (personal)
6	Payment for expert testimony	□ None  Topic editor (personal)	Personal, medical expert testimony
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None  Clinical Director, Anti-NMDA Receptor Encephalitis Foundation	Unpaid
11	Stock or stock options	□ None  ANI Pharmaceuticals  Parabon Nanolabs	Personal Stock options (personal)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None  Horizon Therapeutics  AVID Radiopharmaceuticals	Material support of clinical trial (NCT04372615) In-kind contribution of radiotracer to institution for active research study
13	Other financial or non-financial interests	X None	
Plea:	•	to the following statement to indicate your agreement to answered every question and have not altered the wo	

 Date:
 3/15/2024

 Your Name:
 Charlene Supnet-Bell

 Manuscript Title:
 Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease

 Manuscript Number (if known):
 ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials, medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.			
			Time frame: past 36 months	5

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Pleas	se place an "X" next	to the following statement to indicate your agreeme	nt:
Χ	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/9/2025
Your Name:	Xiong Xu
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.)  No time limit for this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Χ	None	
	#1 above).			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None			
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None			
13	Other financial or non-financial interests	X None			
	Please place an "X" next to the following statement to indicate your agreement:  Legal of the questions on this form				

Date:			3/27/2024			
Your Name:			Sarah B. Berman			
Manuscript Title:			Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease			
Mai	nuscript Number (if k	known):	ADJ-D-24-02652			
content of your manuscript. "Rela affected by the content of the man a bias. If you are in doubt about w		ript. "Re of the m ot about		t-for-profit third parties whose interests may be at to transparency and does not necessarily indicate it is preferable that you do so.		
-	demiology of hyperte medication is not m	-		acturers of antihypertensive medication, even if		
	em #1 below, report ne for disclosure is th		ort for the work reported in this manuscript wi 6 months.	thout time limit. For all other items, the time		
			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the					
	present manuscript (e.g.,		None			
	-	□ I	None	Payments to institution		
	manuscript (e.g., funding, provision of study materials, medical writing,		None	Payments to institution  Click the tab key to add additional rows.		
	manuscript (e.g., funding, provision of study materials,		None			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing		None			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		None  Time frame: past 36 month	Click the tab key to add additional rows.		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not	NIA		Click the tab key to add additional rows.		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	NIA	Time frame: past 36 month	Click the tab key to add additional rows.		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not	NIA	Time frame: past 36 month	Click the tab key to add additional rows.		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	NIA	Time frame: past 36 month	Click the tab key to add additional rows.		
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	X	Time frame: past 36 month	Click the tab key to add additional rows.		
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	X	Time frame: past 36 month	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None			
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None			
13	Other financial or non-financial interests	X None			
	Please place an "X" next to the following statement to indicate your agreement:  X				

Date:	3/28/2024
Your Name:	Jasmeer P. Chhatwal
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			ne all entities with whom you have this cionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	X	None	Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.			
			Time frame: past 36 month	ıs
2	Grants or contracts from any entity (if not	Х	None	
	indicated in item #1 above).			
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None  Humana Healthcare ExpertConnect Leerink Partners	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None			
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None			
13	Other financial or non-financial interests	X None			
	Please place an "X" next to the following statement to indicate your agreement:  Legal of the questions on this form				

Date:			3/18/2024		
Your Name:			Takeshi Ikeuchi		
Manuscript Title:			Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease		
Maı	nuscript Number (if k	(nown):	ADJ-D-24-02652		
content of your manuscript. "Rela affected by the content of the man		ipt. "Rela of the mai	ted" means any relation with for-profit or no	s/interests listed below that are related to the t-for-profit third parties whose interests may be not to transparency and does not necessarily indicate , it is preferable that you do so.	
		nsion, you		xample, if your manuscript pertains to the acturers of antihypertensive medication, even if	
In item #1 below, report all support frame for disclosure is the past 36			· · · · · · · · · · · · · · · · · · ·	ithout time limit. For all other items, the time	
			l entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	AMED.	P23dk0207066 P22dk0207049	Payment was made to my institute. Payment was made to my institute.	
	article processing charges, etc.) No time limit for this item.				
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not		one		
	indicated in item #1 above).		P23dk0207060 P23ek0109545	Payment was made to my institute  Payment was made to my institute	
		AIVILD	F 2 3 C NO 1 U 9 J 4 J	rayment was made to my institute	
3	Royalties or licenses	X No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None  Eisai Ely Lilly FUJIREBIO Novo Nordics	Payment was made to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Eisai FUJIREBIO Ely Lilly PDR Pharm Roche Diagnostics	Payment was made to me.
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
	Please place an "X" next to the following statement to indicate your agreement:  X		

Date:	3/12/2024
Your Name:	Kensaku Kasuga
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	X	None	Click the tab key to add additional rows.
	No time limit for this item.			
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Х	None	
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
	Please place an "X" next to the following statement to indicate your agreement:  X		

Date:	3/26/2024	
Your Name:	Yoshiki Niimi	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscrint Number (if known):	ADI-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate

a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			ne all entities with whom you have this cionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X	None	Click the tab key to add additional rows.
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	X	None	
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
	Please place an "X" next to the following statement to indicate your agreement:  X		

Date:	3/6/2024
Your Name:	Edward D. Huey
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	X	None	Click the tab key to add additional rows.
	tilis itelli.		<del>-</del> : (	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X	None	s
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Plea X	Please place an "X" next to the following statement to indicate your agreement:  X   Certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/5/2024	
Your Name:	Peter R. Schofield	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None	
	funding, provision of study materials,	NIH	Paid through Wash U to institution
	-	Anonymous Foundation	Paid through Wash U to institution
	medical writing, article processing	Roth Charitable Foundation	Paid to institution.
	charges, etc.) No time limit for this item.		
		Time frame: past 36 month	os —
2	Grants or contracts from any entity (if not	□ None	
	indicated in item	NHMRC (Australia)	Paid to institution
	#1 above).	MRFF (Australia)	Paid to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	X None	
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Plea	se place an "X" next	to the following statement to indicate your agreemen	nt:
Χ	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/26/2024	
Your Name:	William S. Brooks	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
pı m	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
	#1 above).	-		
3	Royalties or licenses	χ	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	3/19/2024	
Your Name:	Natalie S. Ryan	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
pre ma	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
	"I doove,"			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	3/7/2024
Your Name:	Mathias Jucker
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscrint Number (if known)	ADI-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
ļ ļ	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not	Х	None	
	indicated in item #1 above).	I—		
	"1 0.55.6,"	<del> </del>		
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	3/11/2024
Your Name:	Christoph Laske
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease
Manuscript Number (if known):	ADJ-D-24-02652

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
pre ma	All support for the present manuscript (e.g., funding, provision	X	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.)  No time limit for this item.			
	tilis itelli.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
	"I doove,"			
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:			3/18/2024	
Your Name:			Johannes Levin	
Manuscript Title:			Ubiquitin-Proteasome System in the Differe Disease	nt Stages of Dominantly Inherited Alzheimer's
Ма	nuscript Number (if k	nown):	ADJ-D-24-02652	
content of your manuscript. "Rela affected by the content of the ma		ipt. "Rela of the mai	ited" means any relation with for-profit or no	s/interests listed below that are related to the t-for-profit third parties whose interests may be at to transparency and does not necessarily indicate it is preferable that you do so.
epi		nsion, you		xample, if your manuscript pertains to the acturers of antihypertensive medication, even if
	tem #1 below, report a me for disclosure is the			ithout time limit. For all other items, the time
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ No	Time frame: Since the initial planning	of the work
1	present manuscript (e.g., funding, provision	□ <b>N</b> €		
1	present manuscript (e.g., funding, provision of study materials,			Funding for the project
1	present manuscript (e.g., funding, provision of study materials, medical writing,			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing			Funding for the project
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)			Funding for the project
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing			Funding for the project
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		one	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.			Funding for the project  Click the tab key to add additional rows.
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	DZNE	one	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE N	Time frame: past 36 month	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	DZNE N.	Time frame: past 36 month	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE  Note: The second of the	Time frame: past 36 month  one  n Ministry for Research and Education	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE  Note: The second of the	Time frame: past 36 month  one  n Ministry for Research and Education within the CLINSPECT-M Cluster	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE  Note: The second of the	Time frame: past 36 month  one  n Ministry for Research and Education within the CLINSPECT-M Cluster and Petra Ehrmann foundation	Funding for the project  Click the tab key to add additional rows.
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE    No.	Time frame: past 36 month  one  In Ministry for Research and Education In within the CLINSPECT-M Cluster and Petra Ehrmann foundation tionsfonds	Funding for the project  Click the tab key to add additional rows.  Institution  Institution  Institution
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE    No.	Time frame: past 36 month  one  In Ministry for Research and Education In within the CLINSPECT-M Cluster In Mendation It within the CLINSPECT-M Cluster It within the CLINSPECT-	Funding for the project  Click the tab key to add additional rows.  Institution  Institution  Institution  Institution  Institution
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	DZNE  N Germal (BMBF) Anton a Innovat Michae Jerome Alzhein	Time frame: past 36 month  one  In Ministry for Research and Education In Within the CLINSPECT-M Cluster In Mend Petra Ehrmann foundation Itionsfonds In J Fox Foundation for Parkinson's Research I LeJeune Foundation	Funding for the project  Click the tab key to add additional rows.  Institution  Institution  Institution  Institution  Institution  Institution  Institution

Compensation for service as CMO

MODAG GmbH

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		(DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198) DZNE	Compensation for deputy lead of clinical trial unit
3	Royalties or licenses	X None	
4	Consulting fees	□ None  EISAI  Biogen	To me To me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Bayer Vital Biogen EISAI TEVA Roche Zambon	To me
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
8	Patents planned, issued or pending	□ None			
		Oral Phenylbutyrate for Treatment of Human 4- Repeat Tauopathies" (EP 23 156 122.6)	filed by LMU Munich		
		Pharmaceutical Composition and Methods of Use" (EP 22 159 408.8)	filed by MODAG GmbH		
9	Participation on a Data Safety Monitoring	□ None			
	Board or Advisory Board	Axon Neuroscience	to me		
10	Leadership or fiduciary role in other board, society,	□ None			
	committee or	ERN-RND Management board ERN-RND Atypical Parkinson Disease Coordinator	unpaid unpaid		
	advocacy group, paid or unpaid				
11	Stock or stock options	X None			
12	Receipt of equipment, materials, drugs,	X None			
	medical writing, gifts or other				
	services				
13	Other financial or non-financial interests	X None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
χ	I certify that I have	answered every question and have not altered the wor	ding of any of the questions on this form.

Date:	3/19/2024	
Your Name:	Jonathan Vöglein	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	X	None	
	funding, provision of study materials,			
	medical writing,			Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
	"I doove,"			
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	3/20/2024	
Your Name:	Jee Hoon Roh	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	X	None	
	funding, provision of study materials,			
	medical writing,			Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	S
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			
	"I doove,"			
3	Royalties or licenses		None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	_4/22/2024	
Your Name:	Francisco Lopera	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision	Х	None	
	of study materials,			
	medical writing, article processing			Click the tab key to add additional rows.
	charges, etc.) No time limit for			
	this item.			
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).	I—		
	"1 0.557.	l⊢		
3	Royalties or licenses	Х	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	
10	Leadership or fiduciary role in	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	

Date:	3/28/2024		
	3/20/2024	_	
Your Name:	Randall J. Bateman		
Manuscript Title:	Ubiquitin-Proteasome System in the Different Disease	nt Stages of Dominantly Inherited Alzheimer's	
Manuscript Number (if kn	own): ADJ-D-24-02652		
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			
	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g.,	□ None	
	funding, provision	National Institute on Aging UFAG03243	PI: Randall Bateman, DIAN - grant
	of study materials, medical writing,		Click the tab key to add additional rows.
	article processing		Click the tab key to add additional rows.
	charges, etc.)  No time limit for		
	this item.		
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not	□ None	
	indicated in item #1 above).	National Institute on Aging R01AG068319	PI: Randall Bateman DIAN-TU Next Generation Tau Trial - grant
		Alzheimer's Association DIAN-TU-OLE-21-725093 DIAN-TU-Tau-21-822987	PI: Randall Bateman DIAN-TU Open Label Extension – grant DIAN-TU Tau Next Generation - grant
		Biogen	Tau SILK Consortium member NfL Consortium member
		AbbVie	Tau SILK Consortium member NfL Consortium member
		Bristol Meyer Squibbs	NfL Consortium member
		Novartis	Tau SILK Consortium member
		National Institute on Aging UFAG03243	PI: Randall Bateman, DIAN - grant

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		National Institute on Aging RF1AG061900, R56AG061900	PI: Randall Bateman, Blood AB - grant
		National Institute on Aging R21AG067559	PI: Randall Bateman, NfL - grant
		NINDS/NIA R01NS095773	PI: Randall Bateman, CNS Tau - grant
		Centene Corporation	Investigator Initiated Research - grant
		Rainwater Foundation	Investigator Initiated Research - grants
		Assn for Frontotemporal Degeneration FTD Biomarkers Initiative	Investigator Initiated Research - grant
		Biogen	Investigator Initiated Research – grant
		BrightFocus Foundation	Investigator Initiated Research – grant
		Cure Alzheimer's Fund	Investigator Initiated Research – grant
		Coins for Alzheimer's Research Trust Fund	Investigator Initiated Research – grant
		Eisai	Investigator Initiated Research – grants
		The Foundation for Barnes-Jewish Hospital	Investigator Initiated Research – grant
		TargetALS	Investigator Initiated Research – grant
		Good Ventures Foundation	Investigator Initiated Research – grant
		National Institute on Aging	PI: Randall Bateman DIAN-TU Next Generation
		R01AG53627/R56AG53627	Prevention Trial - Research Grant
		DIAN-TU Pharma Consortium	Active: Eli Lilly and Company/Avid
			Radiopharmaceuticals, Hoffman-La
			Roche/Genentech, Biogen, Eisai, Janssen.
			Previous: Abbvie, Amgen, AstraZeneca, Forum,
			Mithridion, Novartis, Pfizer, United Neuroscience, Sanofi).
		Eli Lilly and Company	Tau SILK Consortium Member.
		Hoffman-La Roche	Receipt of drugs and services. NfL Consortium
		Hoffman-La Roche	Member
		CogState	In-kind support
		Signant	In-kind support
3	Royalties or licenses	□ None	
		C2N Diagnostics	Equity ownership interest in C2N Diagnostics and receive royalty income based on technology (methods of diagnosing AD with phosphorylation changes, stable isotope labeling kinetics, and blood plasma assay) licensed by Washington University to C2N Diagnostics
4	Consulting fees		
		X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
5 Payment or honoraria for lectures,		□ None			
	presentations,	Korean Dementia Association	International Conference Lecture Honoraria		
	speakers	American Neurological Association	Fall Conference honoraria		
	bureaus,	Fondazione Prada	Conference honoraria		
	manuscript	Weill Cornell Medical College	Conference honoraria		
	writing or	Harvard University	Conference honoraria		
	educational events				
6 Payment for expert testimony X None					
7	Support for attending meetings and/or	□ None			
	travel	Hoffman La-Roche	Reimbursed for travel expenses		
		Alzheimer's Association Roundtable	Reimbursed for travel expenses		
		Duke Margolis Alzheimer's Roundtable	Reimbursed for travel expenses		
		BrightFocus Foundation	Reimbursed for travel expenses		
		Tau Consortium Investigator's Meeting	Reimbursed for travel expenses		
		Fondazione Prada	Reimbursed for travel expenses		
		NAPA Advisory Council on Alzheimer's Research	Reimbursed for travel expenses		
8	Patents planned, issued or pending	□ None			
		Washington University w/ RJB as coinventor - Methods for Measuring the Metabolism of CNS Derived Biomolecules In Vivo	US nonprovisional patent application 12/267,974		
		Washington University w/ RJB as coinventor - Methods for Measuring the Metabolism of neurally Derived Biomolecules in vivo	US nonprovisional patent application 13/005,233		
		Washington University w/ RJB as coinventor - Plasma based methods for detecting CNS Amyloid Disposition	US nonprovisional patent application 62/492,718		
		Washington University w/ RJB as coinventor - Plasma based methods for determining A-Beta Amyloidosis	US nonprovisional patent application 16/610,428		
		Washington University w/RJB as coinventor – Methods of Treating Based on site-specific tau phosphorylation	US nonprovisional patent application 17/015,985		
		Washington University w/RJB as coinventor – Tau Kinetic Measurements	US nonprovisional patent application 15/515,909		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
9	Participation on a Data Safety Monitoring	□ None		
	Board or Advisory Board	Hoffman La-Roche/Genentech	Unpaid - Gantenerumab Advisory Board	
	Mayisory Board	Biogen – Combination therapy for Alzheimer's disease	Unpaid Scientific Advisory Board	
		UK Dementia Research Institute at University College London	Unpaid Scientific Advisory Board	
		Stanford University, Next Generation Translational Proteomics for Alzheimer's and Related Dementias	Unpaid Scientific Advisory Board	
10	Leadership or fiduciary role in other board,	□ None		
	society, committee or advocacy group,	C2N Diagnostics	Receives income from C2N Diagnostics for serving on the scientific advisory board	
	paid or unpaid			
			-	
11	Stock or stock options	X None		
12	Receipt of equipment, materials, drugs,	□ None		
	medical writing, gifts or other services	Eisai	Receipt of drugs and services, DIAN-TU Next Generation Trial	
		Janssen	Receipt of drugs and services, DIAN-TU Next Generation Trial	
		Hoffman La Roche	Receipt of drugs and services, DIAN-TU Open Label Extension - Gantenerumab	
13	Other financial or non-financial interests	X None		
Plea	Please place an "X" next to the following statement to indicate your agreement:			
Χ	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date	e:		1/11/2024		
Your	Name:		Carlos Cruchaga		
Manuscript Title:			Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease		
Man	uscript Number (if k	(nown):	ADJ-D-24-02652		
cont affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			t-for-profit third parties whose interests may be nt to transparency and does not necessarily indicate	
epid		nsion, yo		xample, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th			thout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIA Alzhein	one  mer's Association	PI: Carlos Cruchaga grant PI: Carlos Cruchaga grant PI: Carlos Cruchaga grant PI: Carlos Cruchaga grant	
			Time frame: past 36 month	is	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X N	one		
3	Royalties or licenses	X N	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None  Circular Genomics  Alector	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None	
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	□ None  Somalogic- ASHG 2023	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None  Vivid Genetics  Circular Genomics	
11	Stock or stock options	□ None  Vivid Genetics  Circular Genomics	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	Received research support from: GSK Alector Biogen EISAI	Anonymous Foundation Alzheimer's Association Biogen Parabon
Plea:	Please place an "X" next to the following statement to indicate your agreement:  X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	3/6/2024	
Your Name:	Eric McDade	
Manuscript Title:	Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease Click or tap here to enter text.	
Manuscript Number (if known):	ADJ-D-24-02652	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g.,	□ None		
	funding, provision of study materials,	National Institute of Aging U19AG032438	Sub-I: Eric McDade; DIAN-grant	
	medical writing,		Click the tab key to add additional rows.	
	article processing charges, etc.) No time limit for this item.			
		Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not	□ None		
	indicated in item	National Institute of Aging: U01AG059798	PI: Eric McDade; Primary Prevention Trial	
	#1 above).	Alzheimer's Association	Investigator Initiated Research - grant	
		National Institute of Aging: R13AG055232	PI: Eric McDade; DIAD Family conference – grant	
		National Institute of Aging	PI: Eric McDade; K-award grant	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	□ None	
		C2N Diagnostics	Co-inventor of technology "methods of diagnosing and treating based on site-specific tau phosphorylation" and will receive part of the profits from any sales of this test that are licensed to C2N Diagnostics which has licensed CSF methods from Washington University.
4	Consulting fees	X None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None  Eisal  AAN	Honoraria
6	Payment for expert testimony	X None	
7	Support for attending meetings and/or travel	Alzheimer Association Alnylum Fondation Alzheimer er Travel reimbursement Amsterdam UMC Roche Alzheimer's Association	Travel reimbursement Travel reimbursement Travel reimbursement Travel reimbursement

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None  Eli Lilly NIA Alector Cumulus Neuroscience Ltd SAGE Therapeutics	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None  Fondation Alzheimer  Alzamend	
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	X None	
Pleas	se place an "X" next	to the following statement to indicate your agreeme	nt:

			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		ding of any of the questions on this form.		